Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538).
Joseph Grosso
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Christine E. Horak
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
David Inzunza
Employment or Leadership Position - Bristol-Myers Squibb
Diana M. Cardona
Consultant or Advisory Role - Bristol-Myers Squibb
Jason S. Simon
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Ashok Kumar Gupta
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Vindira Sankar
Employment or Leadership Position - Bristol-Myers Squibb
Jong-Soon Park
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Georgia Kollia
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Janis M. Taube
Research Funding - Bristol-Myers Squibb
Robert Anders
Research Funding - Bristol-Myers Squibb
Other Remuneration - Bristol-Myers Squibb
Maria Jure-Kunkel
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Jim Novotny, Jr.
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Clive R. Taylor
Honoraria - DAKO
Xiaoling Zhang
Employment or Leadership Position - DAKO
Therese Phillips
Employment or Leadership Position - DAKO
Pauline Simmons
Employment or Leadership Position - DAKO
John Cogswell
Employment or Leadership Position - Bristol-Myers Squibb